CD4/CD8–p56lck Induced T-Cell Receptor Signaling and Its Implications for Immunotherapy
Biomolecules · 2025
DOI: 10.3390/biom15081096 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Andres Oroya und 1 weiteren Autor:innen. Beteiligte Einrichtung: Département de Médicine, Université de Montréal, Montréal, QC H3C 3J7, Canada. Hauptthemen laut MEDLINE: Signal Transduction, Immunotherapy, Receptors, Antigen, T-Cell, Lymphocyte Specific Protein Tyrosine Kinase p56(lck). Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, Canadian Institutes of Health Research Foundation.
Abstract (Originalsprache)
T-cells constitute an essential component of the adaptive immune response, mount a protective response against foreign pathogens and are important regulators of anti-tumor immunotherapy. In this context, the activation of T-cells and chimeric antigen receptor (CAR)-expressing T-cells is orchestrated by various signaling pathways, involving the initiation of a protein tyrosine phosphorylation cascade. For T-cells, this involves initiation of the phosphorylation cascade via src-related protein-tyrosine kinase p56lck, which we show to associate with the co-receptors CD4 and CD8 for the induction of a phosphorylation cascade needed for the activation of T-cells. Likewise, p56lck phosphorylation of the antigen receptor immunoreceptor tyrosine-based activation motifs (ITAMs) and key CD28 tyrosine motifs ensures the functionality and the survival of CARs, while their phospho-targets are also inhibited by PD-1, a key component of the immune checkpoint blockade. This review covers historic and current elements of our knowledge of CD4/CD8–p56lck-induced activation events and their importance to the development of CAR T-cell immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Département de Médicine, Université de Montréal, Montréal, QC H3C 3J7, Canada.
- Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H3T 1J4, Canada.
- L'unité, Signalisation Cellulaire en Immunothérapie, Centre de Recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR), Montréal, QC H1T 2M4, Canada.
- Institut Universitaire d'Hématologie-Oncologie & Thérapie Cellulaire de Montréal, Hôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, Canada.
- Department of Medicine, McGill University, Montréal, QC H3A 2B4, Canada.
- ImmunAb Research Inc., 2300 Blvd Alfred-Nobel, Montréal, QC H4S 2A4, Canada.
ORCID-Profile: Andres Oroya
Förderung
- NIAID NIH HHS
- NIH HHS
- Canadian Institutes of Health Research Foundation
- Canadian Institutes of Health Research Foundation grant
- National Institutes of Health grant
Zitieren
APA
Oroya, A., & Rudd, C. E. (2025). CD4/CD8–p56lck Induced T-Cell Receptor Signaling and Its Implications for Immunotherapy. Biomolecules. https://doi.org/10.3390/biom15081096
Vancouver
Oroya A, Rudd CE. CD4/CD8–p56lck Induced T-Cell Receptor Signaling and Its Implications for Immunotherapy. Biomolecules. 2025. doi:10.3390/biom15081096
BibTeX
@article{Oroya2025,
author = {Oroya, Andres and Rudd, Christopher E},
title = {CD4/CD8–p56lck Induced T-Cell Receptor Signaling and Its Implications for Immunotherapy},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15081096}
}
EUVIMED